Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer, a leader in health innovations, has launched the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 for accelerated detection of SARS-CoV-2 variants, including Omicron. The kit enhances sequencing throughput and reduces turnaround time by three hours for 96 samples through advanced normalization beads. It incorporates 1,536 Unique Dual Index barcodes, allowing for the sequencing of 6,000 libraries in a single flow cell, lowering costs. This initiative aims to support SARS-CoV-2 surveillance efforts amid the ongoing pandemic.
PerkinElmer, Inc. (NYSE: PKI) announced that its SARS-CoV-2 RT-PCR assays remain effective despite the emergence of the Omicron variant of concern.
With over 30 reported mutations in the S gene, the company's assays do not target this gene and are unaffected by these changes. In silico assessments indicate no impact on diagnostic accuracy from the Omicron variant.
The company emphasizes the importance of reliable diagnostics amid ongoing concerns regarding transmissibility and vaccine resistance. PerkinElmer's solutions include a comprehensive SARS-CoV-2 portfolio.
PerkinElmer, a global leader in health innovation, will present at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET. Prahlad Singh, the Company’s CEO, will discuss strategic priorities and provide a company update. Interested parties can register for the event here. A webcast will be available on PerkinElmer's Investor website, with a replay accessible for 90 days post-event.
PerkinElmer, a global leader in health innovation, will present at the virtual 2021 Stifel Healthcare Conference on November 16, 2021, at 8:40 a.m. ET. Senior VP and CFO Jamey Mock will discuss the company's strategic priorities. Interested participants can register for the event here. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after.
PerkinElmer reported third quarter 2021 revenue of $1.17 billion, reflecting 21% growth year-over-year, with 12% organic growth. GAAP earnings per share (EPS) from continuing operations fell to $1.11, down from $1.57 in Q3 2020, while adjusted EPS increased to $2.31 from $2.09. The company raised its full-year guidance, forecasting adjusted revenue of $4.9 billion and EPS of $10.81. Key segments, Diagnostics and Discovery & Analytical Solutions, both saw significant revenue increases, contributing to a strong financial outlook.
PerkinElmer, Inc. (NYSE: PKI) has released its 2021 Corporate Social Responsibility (CSR) Report, detailing its progress in environmental, social, and governance (ESG) initiatives. The report highlights a 8.5% reduction in Scope 1 and 2 emissions, a 15% decrease in hazardous waste, and increased female representation in leadership roles to 31%. Four new commitments were announced, targeting carbon neutrality by 2040, waste reduction by 2025, and enhancing female leadership. The company aims to maintain transparency in its ESG goals under SASB guidelines.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of
PerkinElmer (NYSE: PKI) and Honeycomb Biotechnologies have launched the innovative HIVETM scRNAseq Solution, designed for single-cell isolation and analysis. This portable device allows the capture, storage, and RNA sequencing of fragile cell types without the need for specialized equipment, enhancing research opportunities. The HIVE solution maintains sample integrity, improving workflow efficiency for multi-site studies. This technology aims to drive advancements in diagnostics and therapeutic development, particularly for academic collaborations and clinical trials.
PerkinElmer, Inc. (NYSE: PKI) announced it will release its third quarter 2021 financial results on November 2, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results, featuring CEO Prahlad Singh and CFO Jamey Mock. Investors can access a live audio webcast via the company’s website. A replay of the call will be available after 7:00 p.m. ET on the same day. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and aims to innovate for a healthier world.
PerkinElmer, NYSE:PKI, has received Emergency Use Authorization (EUA) from the FDA for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1. This test allows labs to simultaneously detect and differentiate between SARS-CoV-2, influenza A, influenza B, and RSV from respiratory samples. The test aims to streamline testing during the flu season, helping to alleviate confusion from similar symptoms. PerkinElmer's existing CE marking for this test in over 30 countries is also noted. The company reported revenues of approximately $3.8 billion in 2020.
FAQ
What is the market cap of PERKINELMER (PKI)?
